2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

J. Herrstedt; R. Clark-Snow; C. H. Ruhlmann; A. Molassiotis; I. Olver; B. L. Rapoport; M. Aapro; K. Dennis; P. J. Hesketh; R. M. Navari; L. Schwartzberg; M. L. Affronti; M. A. Garcia-Del-Barrio; A. Chan; L. Celio; R. Chow; M. Fleury; R. J. Gralla; R. Giusti; F. Jahn; H. Iihara; E. Maranzano; V. Radhakrishnan; M. Saito; P. Sayegh; S. Bosnjak; L. Zhang; J. Lee; V. Ostwal; T. Smit; A. Zilic; K. Jordan; F. Scotté

doi:10.1016/j.esmoop.2023.102195

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

J. Herrstedt
, R. Clark-Snow
, C. H. Ruhlmann
, A. Molassiotis
, I. Olver
, B. L. Rapoport
, M. Aapro
, K. Dennis
, P. J. Hesketh
, R. M. Navari
, L. Schwartzberg
, M. L. Affronti
, M. A. Garcia-Del-Barrio
, A. Chan
, L. Celio
, R. Chow
, M. Fleury
, R. J. Gralla
, R. Giusti
, F. Jahn

H. Iihara, E. Maranzano, V. Radhakrishnan, M. Saito, P. Sayegh, S. Bosnjak, L. Zhang, J. Lee, V. Ostwal, T. Smit, A. Zilic, K. Jordan, F. Scotté^*

^*Corresponding author for this work

Zealand University Hospital Roskilde and Naestved
Københavns Universitet
Oncology Supportive Care Consultant
Odense University Hospital
University of Southern Denmark
Faculty of Health and Medical Sciences
The Medical Oncology Centre of Rosebank
Faculty of Health Sciences
Genolier Cancer Center
University of Ottawa
Lahey Clinic Medical Center, Burlington
World Health Organization Regional Office for Africa
University of Nevada, Reno School of Medicine
Duke University
Clínica Universidad de Navarra
Universidad de Navarra
Independent Medical Oncologist
University of Toronto Faculty of Medicine
University of Lausanne
Albert Einstein College of Medicine of Yeshiva University
Università degli Studi di Roma La Sapienza
University Hospital Halle (Saale)
Gifu University Hospital
Università degli Studi di Perugia
Cancer Institute (WIA)
Juntendo University School of Medicine
OU Health Stephenson Cancer Center
Institute for Oncology and Radiology of Serbia
Yonsei University
Tata Memorial Hospital
Ernst von Bergmann Hospital
Universitat Heidelberg
Unité Mixte de Recherche (UMR) 1170

Research output: Contribution to journal › Article › peer-review

155 Citations (SciVal)

2 Downloads (Pure)

Abstract

Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial.
The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015.1 This article is an update of the 2015 guidelines.

Original language	English
Article number	102195
Number of pages	18
Journal	ESMO Open
Volume	9
Issue number	2
Early online date	11 Jan 2024
DOIs	https://doi.org/10.1016/j.esmoop.2023.102195
Publication status	Published - 1 Feb 2024

Bibliographical note

Copyright © 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND
license (https://creativecommons.org/licenses/by-nc-nd/4.0/).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

chemotherapy
MASCC–ESMO Clinical Practice Guideline
nausea and vomiting
prevention
radiotherapy

Access to Document

10.1016/j.esmoop.2023.102195Licence: CC BY-NC-ND 4.0

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
Copyright © 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Final published version, 763 KBLicence: CC BY-NC-ND 4.0

Cite this

Herrstedt, J., Clark-Snow, R., Ruhlmann, C. H., Molassiotis, A., Olver, I., Rapoport, B. L., Aapro, M., Dennis, K., Hesketh, P. J., Navari, R. M., Schwartzberg, L., Affronti, M. L., Garcia-Del-Barrio, M. A., Chan, A., Celio, L., Chow, R., Fleury, M., Gralla, R. J., Giusti, R., ... Scotté, F. (2024). 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open, 9(2), Article 102195. https://doi.org/10.1016/j.esmoop.2023.102195

@article{2365f2dc7e70438f99b2e10daf680e79,

title = "2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting",

abstract = "Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial. The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015.1 This article is an update of the 2015 guidelines.",

keywords = "chemotherapy, MASCC–ESMO Clinical Practice Guideline, nausea and vomiting, prevention, radiotherapy",

author = "J. Herrstedt and R. Clark-Snow and Ruhlmann, \{C. H.\} and A. Molassiotis and I. Olver and Rapoport, \{B. L.\} and M. Aapro and K. Dennis and Hesketh, \{P. J.\} and Navari, \{R. M.\} and L. Schwartzberg and Affronti, \{M. L.\} and Garcia-Del-Barrio, \{M. A.\} and A. Chan and L. Celio and R. Chow and M. Fleury and Gralla, \{R. J.\} and R. Giusti and F. Jahn and H. Iihara and E. Maranzano and V. Radhakrishnan and M. Saito and P. Sayegh and S. Bosnjak and L. Zhang and J. Lee and V. Ostwal and T. Smit and A. Zilic and K. Jordan and F. Scott{\'e}",

note = "Copyright {\textcopyright} 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).",

year = "2024",

month = feb,

day = "1",

doi = "10.1016/j.esmoop.2023.102195",

language = "English",

volume = "9",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "Elsevier",

number = "2",

}

Herrstedt, J, Clark-Snow, R, Ruhlmann, CH, Molassiotis, A, Olver, I, Rapoport, BL, Aapro, M, Dennis, K, Hesketh, PJ, Navari, RM, Schwartzberg, L, Affronti, ML, Garcia-Del-Barrio, MA, Chan, A, Celio, L, Chow, R, Fleury, M, Gralla, RJ, Giusti, R, Jahn, F, Iihara, H, Maranzano, E, Radhakrishnan, V, Saito, M, Sayegh, P, Bosnjak, S, Zhang, L, Lee, J, Ostwal, V, Smit, T, Zilic, A, Jordan, K & Scotté, F 2024, '2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting', ESMO Open, vol. 9, no. 2, 102195. https://doi.org/10.1016/j.esmoop.2023.102195

TY - JOUR

T1 - 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

AU - Herrstedt, J.

AU - Clark-Snow, R.

AU - Ruhlmann, C. H.

AU - Molassiotis, A.

AU - Olver, I.

AU - Rapoport, B. L.

AU - Aapro, M.

AU - Dennis, K.

AU - Hesketh, P. J.

AU - Navari, R. M.

AU - Schwartzberg, L.

AU - Affronti, M. L.

AU - Garcia-Del-Barrio, M. A.

AU - Chan, A.

AU - Celio, L.

AU - Chow, R.

AU - Fleury, M.

AU - Gralla, R. J.

AU - Giusti, R.

AU - Jahn, F.

AU - Iihara, H.

AU - Maranzano, E.

AU - Radhakrishnan, V.

AU - Saito, M.

AU - Sayegh, P.

AU - Bosnjak, S.

AU - Zhang, L.

AU - Lee, J.

AU - Ostwal, V.

AU - Smit, T.

AU - Zilic, A.

AU - Jordan, K.

AU - Scotté, F.

N1 - Copyright © 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PY - 2024/2/1

Y1 - 2024/2/1

N2 - Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial. The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015.1 This article is an update of the 2015 guidelines.

AB - Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial. The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015.1 This article is an update of the 2015 guidelines.

KW - chemotherapy

KW - MASCC–ESMO Clinical Practice Guideline

KW - nausea and vomiting

KW - prevention

KW - radiotherapy

UR - https://www.sciencedirect.com/science/article/pii/S2059702923014369?via%3Dihub

UR - https://www.scopus.com/pages/publications/85186223196

U2 - 10.1016/j.esmoop.2023.102195

DO - 10.1016/j.esmoop.2023.102195

M3 - Article

C2 - 38458657

AN - SCOPUS:85186223196

SN - 2059-7029

VL - 9

JO - ESMO Open

JF - ESMO Open

IS - 2

M1 - 102195

ER -

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this